



Exploring Phytoconstituents as Potential Therapeutics for Poly Cystic Ovarian Syndrome: A Comprehensive Review

Sumit S. Mutha*¹, Dr. Laxmidhar Maharana²

¹Research Scholar, Department of Pharmacology School of Pharmaceutical Sciences Shiksha O Anusandhan Deemed to be University Kalinganagar, Bhubaneswar,

²Department of Pharmacology School of Pharmaceutical Sciences, Shiksha O Anusandhan Deemed to be University Kalinganagar, Bhubaneswar,

(Received: 04 February 2024

Revised: 11 March 2024

Accepted: 08 April 2024)

KEYWORDS

Poly Cystic Ovarian Syndrome (PCOS), Phytoconstituents, Herbal Medicine, Insulin Resistance, Hormonal Imbalances, Reproductive Health.

ABSTRACT:

Poly Cystic Ovarian Syndrome (PCOS) is a complex and prevalent endocrine disorder affecting women of reproductive age. This comprehensive review explores the potential of phytoconstituents as therapeutics for PCOS. PCOS is characterized by hormonal imbalances, metabolic disturbances, and reproductive abnormalities. Current treatment options are associated with limitations and side effects, necessitating the exploration of alternative therapeutic approaches. Phytoconstituents, derived from plants, offer a diverse range of bioactive compounds with the potential to address multiple facets of PCOS pathophysiology. This review synthesizes existing research on phytoconstituents such as curcumin, resveratrol, and berberine, highlighting their efficacy in mitigating insulin resistance, modulating hormonal imbalances, and improving reproductive outcomes. The review discusses preclinical and clinical studies, providing insights into the regulatory aspects of these phytoconstituents. The findings suggest that phytoconstituents present a promising avenue for the development of novel therapeutic interventions for PCOS, offering a potential solution with fewer adverse effects. However, further research is warranted to elucidate the mechanisms of action and ensure the safety and efficacy of phytoconstituents in the management of PCOS.

Introduction

One of the most common endocrine illnesses is Poly Cystic Ovarian Syndrome (PCOS), which affects women in their reproductive age range (15–49 years old) and is characterised by a diverse hereditary condition. [1] PCOS has become increasingly common; data from the Global Burden of Disease (GBD) in 2019 showed that the number of cases increased by 30.4% between 1990 and 2019, totaling an astounding 66 million cases globally. PCOS is defined by chronic oligo-anovulation or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology. It is diagnosed using the Rotterdam criteria. [2]

Complex symptoms including ovarian enlargement, hyperandrogenism, insulin resistance, hyperinsulinemia, irregular menstruation, anovulation or oligoanovulation,

infertility, and an increased risk of metabolic disorders, type 2 diabetes, cardiovascular diseases, and obesity are all part of PCOS's clinical manifestations. Oral contraceptives, antiandrogens, insulin sensitizers, and ovulation-stimulating medications are the mainstays of current therapy modalities. However, these medications have accompanying side effects and only offer transient symptom relief. [3]

A growing number of people are interested in studying phytoconstituents obtained from medicinal herbs and plants as a means of finding more sustainable and effective treatment alternatives. These phytochemicals, generally taken from traditional Chinese medicine (TCM) and medicinal plants, have substantial potential in relieving PCOS symptoms. Their potential to address oxidative stress, obesity, anovulation, hyperinsulinemia,



hyperandrogenism, insulin resistance, abnormalities in ovarian morphology and function, and oligomenorrhea associated with PCOS has been brought to light by recent investigations. [4]

Despite the promising strides in this field, there exists a need for a comprehensive review to systematically document the advancements in bioactive phytoconstituents and their mechanisms of action in treating PCOS. This review aims to fill this gap by focusing on three major classes of phytochemicals—flavonoids, polyphenols, and alkaloids—extracted from TCM and plants. Through a thorough exploration of existing literature, this review seeks to provide a comprehensive understanding of the potential therapeutic effects of phytoconstituents in the management of PCOS.

Phytoconstituents, derived from plant sources, represent a diverse array of chemical compounds that contribute to the therapeutic properties of medicinal plants. In the context of Polycystic Ovary Syndrome (PCOS), these phytoconstituents encompass a wide range of compounds, including but not limited to flavonoids, polyphenols, alkaloids, and other bioactive molecules. The significance of phytoconstituents lies in their potential to address various symptoms associated with PCOS, offering a natural and holistic approach to treatment. Understanding the definition and classification of these phytoconstituents becomes paramount in unraveling their complex interactions with PCOS pathology.

The realm of phytoconstituents with potential benefits in PCOS is vast and varied. Flavonoids, such as quercetin, soy isoflavones, and naringenin, showcase promising therapeutic effects by modulating steroidogenic enzymes, hormonal balance, and gut microbiota. Polyphenols like resveratrol, curcumin, catechin, and gallic acid have been explored for their multifaceted impacts on PCOS, ranging from hormonal regulation to anti-inflammatory and antioxidant properties. The diversity of these phytoconstituents offers a rich pool of natural compounds that may contribute to the comprehensive management of PCOS symptoms.

Phytoconstituents exert their effects on PCOS through intricate mechanisms that involve hormonal regulation, anti-inflammatory actions, and modulation of metabolic pathways. For instance, flavonoids like quercetin and soy

isoflavones impact steroidogenic enzymes, while polyphenols like resveratrol and curcumin interact with signaling pathways such as Akt/PKB and NF- κ B. Understanding these mechanisms is crucial for deciphering how phytoconstituents intervene in the complex etiology of PCOS. From disrupting gene expression to influencing cellular pathways, the mechanisms of action of phytoconstituents provide a foundation for their potential as therapeutic agents in PCOS management.[5]

This overview sets the stage for a deeper exploration of individual phytoconstituents and their specific contributions to PCOS treatment, emphasizing the intricate interplay between these natural compounds and the multifaceted nature of PCOS pathology.

THE PATHOGENESIS OF POLYCYSTIC OVARY SYNDROME

A complex endocrine condition known as polycystic ovary syndrome (PCOS) is marked by a number of hormone imbalances and abnormalities related to metabolism. Complex interplay between genetic, environmental, and hormonal factors play a role in the development of PCOS. Genetic predisposition is important because people with a family history of PCOS are more likely to develop the illness themselves. Numerous potential genes that affect ovarian function, androgen metabolism, insulin signalling, and other features have been linked to PCOS through studies. PCOS can also develop and worsen as a result of environmental variables such nutrition, lifestyle, and exposure to endocrine-disrupting substances. [6]

Insulin resistance, a condition in which the body's cells lose their sensitivity to the regulating effects of insulin and instead produce compensatory hyperinsulinemia, is a defining characteristic of PCOS. Obesity is a cause of PCOS as well as one of its effects, and it is closely associated with insulin resistance. High insulin causes the ovaries to overproduce androgens, which adds to the hyperandrogenism that is typical of PCOS. Anovulation and the development of ovarian cysts are caused by the dysregulation of sex hormones, specifically an imbalance between luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The clinical manifestations of PCOS, such as irregular menstrual cycles, infertility, and the emergence of secondary problems like metabolic syndrome and cardiovascular



diseases, are all influenced by these hormonal imbalances collectively.

Endocrine organs are intricately involved

In the manifestation of PCOS, various endocrine organs are intricately involved, encompassing the ovaries, testes, pituitary gland, adrenal gland, and pancreas.

Ovary: Within the context of PCOS, the ovaries undergo significant enlargement, increasing in size by 2–4 times and exhibiting a distinctive string-of-pearls morphology due to the presence of numerous fluid-filled sacs known as follicles. These follicles, influenced by an excess of androgens, fail to mature adequately, hindering the release of eggs and resulting in anovulation.

Pituitary Gland: The pituitary gland secretes follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which are essential hormones. Normally, FSH controls the growth and release of eggs, whereas LH controls the ovaries' production of female hormones (progesterone and oestrogen). Nonetheless, PCOS is characterised by an aberrant rise in LH secretion, which increases the synthesis of androgens. Concurrently, there is a decrease in FSH secretion, which affects the development of oocytes as well as ovarian androgen production. The hypothalamic-pituitary-ovarian (HPO) axis is thrown off balance by this hormonal imbalance.

Adrenal Gland: By generating an overabundance of hormones, the adrenal glands aggravate PCOS. Pregnenolone and dehydroepiandrosterone (DHEA) are produced at higher levels in the adrenal cortex in PCOS patients, both during rest and in response to pituitary hormones. This overindulgent manufacturing of adrenal androgens is a characteristic feature of PCOS.

Pancreas: The pancreas is implicated in PCOS through the overproduction of insulin, contributing to insulin resistance. This insulin resistance leads to hyperinsulinemia, prompting the ovaries to produce excessive androgens, culminating in hyperandrogenism and hypertrophy. The heightened insulin requirement to maintain normal glucose and lipid levels underscores the pancreas's role in regulating blood glucose and lipid levels. [7]

Bioactive Phytochemicals for Pcos




Figure 1: Therapeutic pathways of bioactive phytochemicals in PCOS.

The therapeutic pathways of bioactive phytochemicals in PCOS are depicted in Figure 1. Women who are of reproductive age are affected by PCOS, a hormonal condition. Numerous symptoms, including as irregular periods, excessive hair growth, acne, and weight gain, might be brought on by it. Bioactive phytochemicals have the potential to alleviate PCOS symptoms via various mechanisms. Several of the main routes consist of:

Increasing sensitivity to insulin: Insulin resistance, or the body's cells' inability to use insulin as needed, is frequently linked to PCOS. Numerous health issues, including type 2 diabetes, may result from this. Because bioactive phytochemicals activate AMPK, a protein involved in metabolism regulation, they can enhance insulin sensitivity.

Reducing inflammation: Inflammation is another key factor in PCOS. Bioactive phytochemicals can help to reduce inflammation by inhibiting the NF-κB pathway, a signaling pathway that promotes inflammation.

Improving antioxidant defenses: PCOS is also associated with oxidative stress, which is damage to cells caused by free radicals. Bioactive phytochemicals can help to improve antioxidant defenses by increasing levels of glutathione (GSH), an important antioxidant.

Regulating hormones: PCOS is caused by an imbalance of hormones, including androgen excess and insulin resistance. Bioactive phytochemicals can help to regulate hormones by binding to hormone receptors and preventing them from being activated.



Bioactive phytochemicals can interact with a number of different genes and proteins. This suggests that they may have a variety of different effects on the body.

Overall, bioactive phytochemicals studies included in table 1 have the potential to be a safe and effective

treatment for PCOS. However, more research is needed to confirm these findings and to determine the best way to use bioactive phytochemicals for the treatment of PCOS.

Table 1: Bioactive phytochemicals studies highlighting the safe and effective treatment for PCOS

Sr. No.	Summary	Reference
1	The chapter explores the potential of herbs as medicinal food against obesity, offering promising alternatives to conventional antiobesity drugs.	[8]
2	This chapter reviews the role of complementary and alternative medicine in treating polycystic ovary syndrome (PCOS), emphasizing the need for compliant and efficacious alternative treatments.	[9]
3	The review provides a comprehensive exploration of the therapeutic potential of diosmetin, a flavonoid found in citrus plants, highlighting its various beneficial activities.	[10]
4	The review provides insights into the sustainability and conservation challenges of the endangered Himalayan medicinal herb <i>Angelica glauca</i> , emphasizing the need for comprehensive research on its biology, ecology, and genetic diversity for effective conservation strategies.	[11]
5	The study explores the development and potential of naringenin nanoparticles in treating letrozole-induced polycystic ovarian syndrome in female Wistar rats, demonstrating protective effects on sex hormones, gut microbiota, and oxidative stress levels.	[12]
6	The review explores the application of nanotechnology to enhance the biological activity of herbal antioxidants for managing various diseases, emphasizing the lack of reported side effects in herbal medicine.	[13]
7	The review provides detailed insights into the etiology, risk factors, treatment strategies, challenges, medicinal agents in clinical trials, and emerging therapeutic targets for Polycystic Ovary Syndrome (PCOS).	[14]
8	The study evaluates the clinical uses, pharmacological effects, and safety of the traditional herbal medication Chai-Ling-Tang/Siryung-tang/Sairei-To, highlighting its diverse therapeutic uses.	[15]
9	The review provides an update on the ethnomedicinal uses, pharmacological activities, phytochemistry, and molecular mechanisms of <i>Punica granatum</i> L. (pomegranate) plant extracts.	[16]
10	The article discusses the ethnomedicinal uses, phytochemistry, pharmacology, toxicology, clinical efficacy, mechanism of action, and nanoparticle synthesis of <i>Trigonella foenum-graecum</i> (fenugreek).	[17]
11	The article reviews herbal medicines effective in treating metabolic syndrome, obesity, and related disorders, emphasizing their potential as safe alternatives with evidence-based pharmacological approaches.	[18]
12	The chapter presents 44 natural products with fertility-regulating activities, highlighting their in vitro and in vivo studies, and briefly discusses natural products undergoing clinical trials for developing new herbal fertility regulators.	[19]
13	Comprehensive insights into PCOS covering etiology, treatment strategies, and emerging therapeutic targets.	[20]
14	Discusses advanced drug delivery systems to enhance the bioavailability of berberine for various therapeutic applications.	[21]
15	Critical analysis of drug delivery systems enhancing the efficacy of anticancer phytoconstituents.	[22]
13	Overview of dietary interventions using bioactive foods for managing diabetes.	[23]
17	Review on phytoconstituents like curcumin, resveratrol, and berberine for managing PCOS symptoms.	[24]
18	Explores the impact of food/medicinal herbs on female reproduction and health.	[25]
19	Review of the beneficial effects of fruit phytoconstituents on NAFLD, focusing on mechanisms of action.	[26]
20	Analysis of the potential role of polyphenols in treating PCOS and associated complications.	[27]



21	Examines the link between acne vulgaris, metabolic syndrome, and the potential role of dietary supplements and phytochemicals.	[28]
----	--	------

Flavonoids: Emerging Stars in Polycystic Ovary Syndrome (PCOS) Management

The complex web of symptoms in PCOS is increasingly finding relief in the diverse world of flavonoids. These plant-based compounds, each with its unique pharmacological toolbox, are emerging as promising players in PCOS management.

Take quercetin, for instance. It shines in regulating hormones, both by dampening steroid-producing enzymes and influencing how genes like CYP17a1 express themselves. Its multifaceted impact extends to other key pathways, like PI3K, further solidifying its potential in PCOS models. Not to be outdone, soy isoflavones join the fight by targeting inflammation and subtly shifting testosterone levels. Naringenin, another flavonoid warrior, tackles steroid enzymes head-on while simultaneously nurturing gut microbiota for improved metabolic health.

The spotlight widens to include baicalin, disrupting gene expression in a way that benefits PCOS. And the list goes on: apigenin balancing hormones, luteolin fine-tuning cell signaling, and rutin boosting insulin sensitivity – each flavonoid showcasing its unique talents in the PCOS arena. But their magic extends beyond hormones. Flavonoids wield antioxidant and anti-inflammatory swords, adding extra layers of protection against the multifaceted challenges of PCOS. This diverse arsenal makes them valuable allies in the quest for comprehensive PCOS management strategies. The provided table offers a detailed peek into the ongoing research, illuminating the specific actions, models, and doses used to unlock the therapeutic potential of these promising phytoconstituents. As research delves deeper, one thing is clear: flavonoids are painting a brighter picture for the future of PCOS management. [29]

Therapeutic Potential of Polyphenols in Polycystic Ovary Syndrome (PCOS): A Multifaceted Approach

Polyphenols, plant-derived bioactive compounds, are emerging as promising therapeutic agents for managing the complex symptoms of PCOS. Their diverse actions extend beyond mere hormonal regulation, encompassing anti-inflammatory, antioxidant, and metabolic modulations. This review highlights the specific effects of key polyphenols in preclinical and clinical studies,

emphasizing their mechanisms of action and potential clinical applications.

Resveratrol: Extensive research indicates Resveratrol's potential in PCOS. Clinical studies reveal its ability to downregulate pro-angiogenic gene expression (VEGF and HIF1) in PCOS women and decrease VEGF levels in granulosa cells. Furthermore, Resveratrol exhibits hormonal regulatory effects, lowering testosterone and DHEA levels in vivo and inhibiting the Akt/PKB signaling pathway in both ovarian interstitial cells and NCI-H295R cells.

Curcumin: This polyphenol demonstrates therapeutic efficacy in PCOS by targeting various pathways. In ovarian granulosa cells, Curcumin inhibits the IRE1 α -XBP1 pathway, downregulates follicular development-related genes, and modulates the PI3K/Akt/mTOR pathway. Additionally, it reduces apoptotic factors and exhibits sustained release characteristics in various in vivo and in vitro PCOS models.

Catechin: Studies employing insulin and hCG-induced PCOS mice models demonstrate Catechin's inhibitory effects on STAT3 signaling, MMP2, and MMP9 expression in the uterus. It also upregulates IRS-1 and PI3K signals while downregulating NF- κ B, suggesting potential benefits for uterine dysfunction in PCOS.

Other Polyphenols: Cinnamon, gallic acid, and mangiferin have also garnered attention for their therapeutic potential in PCOS. These polyphenols exhibit a range of beneficial effects, including enhanced insulin sensitivity, reduced inflammatory cytokine levels, and blocked NF- κ B signaling in various PCOS models.

The diverse actions of various polyphenols offer a multifaceted approach to managing PCOS. Their ability to target numerous pathways, including hormonal regulation, inflammation, oxidative stress, and metabolism, highlights their potential as valuable adjuncts to conventional PCOS treatment strategies. Further research is warranted to optimize dosing, delivery systems, and combination therapies for maximizing the clinical benefits of these promising candidates. [30]



Alkaloids: Unveiling a Promising Avenue for Polycystic Ovary Syndrome (PCOS) Management

Despite their established therapeutic potential in various diseases, alkaloids remain largely unexplored in the context of Polycystic Ovary Syndrome (PCOS). This intriguing gap in research presents a unique opportunity to investigate their efficacy in addressing the complex array of symptoms associated with PCOS. Women with PCOS often face challenges like insulin resistance (IR), elevated androgen levels, chronic inflammation, infertility, and recurrent miscarriage. Current clinical approaches predominantly rely on metformin and insulin sensitizers to manage these symptoms. Intriguingly, berberine (BBR), an isoquinoline alkaloid derived from Traditional Chinese Medicines (TCMs) like *Berberis vulgaris* L. and *Coptis chinensis* Franch, has emerged as a promising candidate for insulin sensitization in PCOS.

Clinical studies have revealed BBR's effectiveness in reducing fasting glucose, fasting insulin, and HOMA-IR, while simultaneously elevating sex hormone-binding globulin (SHBG) levels. Notably, compared to metformin, BBR treatment in women undergoing in vitro fertilization resulted in a higher live birth rate and fewer side effects. BBR's insulin-sensitizing effects are attributed to its multi-pronged approach towards pathway modulation. It influences IRS-1 and the mTOR signaling pathway, thereby enhancing insulin sensitivity. Furthermore, BBR upregulates GLUT4 and modulates both the PI3K/Akt and MAPKs pathways, promoting glucose uptake and mitigating IR. Additionally, BBR's role in inhibiting apoptosis and regulating the expression of key factors involved in IR and inflammation suggests a multifaceted mechanism of action contributing to overall clinical improvement. BBR's potential extends beyond insulin sensitization, exhibiting promising effects in addressing infertility and miscarriage associated with PCOS. Studies demonstrate its ability to promote granulosa cell proliferation and inhibit apoptosis via the PI3K/Akt pathway, potentially enhancing pregnancy rates. Moreover, BBR intervention downregulates LPAR3 and integrin $\alpha\text{v}\beta3$ levels, improving endometrial receptivity and reducing miscarriage risk in PCOS rat models. Interestingly, BBR has also been implicated in alleviating ovarian glucose metabolism disorders in PCOS. By activating the AMPK pathway and promoting SIRT-3 ubiquitination, BBR facilitates ovarian cell glucose uptake and maintains

glucose homeostasis, contributing to metabolic balance within the ovarian microenvironment. [31]

Challenges and Limitations

Variability in Phytoconstituent Composition:

One significant challenge in exploring the therapeutic potential of phytoconstituents for Polycystic Ovary Syndrome (PCOS) lies in the inherent variability of phytoconstituent composition across different plant sources. The diverse array of medicinal herbs and plants used in traditional remedies may contain varying concentrations of bioactive compounds. This variability poses a challenge in ensuring consistent and reproducible effects, hindering the establishment of standardized treatment regimens. The identification and quantification of specific phytoconstituents become crucial for understanding their therapeutic efficacy, necessitating comprehensive studies to unravel the complex chemical profiles of these natural compounds.

Lack of Standardization in Herbal Preparations:

The lack of standardized herbal preparations represents another significant limitation in harnessing the therapeutic potential of phytoconstituents for PCOS. Herbal remedies often involve intricate combinations of multiple phytoconstituents, making it challenging to establish uniform formulations with consistent efficacy. The absence of standardized protocols for the extraction, processing, and dosage of phytoconstituents complicates the translation of research findings into clinically applicable treatments. Standardization efforts are essential to ensure the reproducibility of results and facilitate the integration of phytoconstituent-based therapies into mainstream medical practices.

Variability in Study Designs and Methodologies:

The diverse range of study designs and methodologies employed in research on phytoconstituents for PCOS introduces variability and makes it challenging to draw definitive conclusions. Heterogeneity in experimental models, sample sizes, and outcome measures across different studies can lead to conflicting or inconclusive findings. Standardization of research methodologies, including the use of well-defined animal models, consistent diagnostic criteria for PCOS, and harmonized outcome assessments, is crucial for enhancing the



reliability and comparability of research outcomes. Addressing these methodological variations will contribute to a more cohesive understanding of the therapeutic effects of phytoconstituents in the context of PCOS.

Gaps in Current Research and Future Directions:

Despite the progress made in clinical trials investigating phytoconstituents for PCOS, several gaps and challenges persist in the current research landscape. Variability in study designs, patient populations, and outcome measures poses challenges to data interpretation and synthesis. Further research standardization is essential to facilitate meaningful comparisons and draw robust conclusions. Additionally, the long-term safety and efficacy of phytoconstituent interventions require more extensive investigation. Future research directions should prioritize large-scale, well-controlled clinical trials with extended follow-up periods to assess both short-term and sustained effects. Identifying optimal dosage regimens, elucidating mechanisms of action, and exploring potential synergies between phytoconstituents and conventional treatments represent promising avenues for future investigation. Addressing these gaps will contribute to a more comprehensive understanding of the role of phytoconstituents in PCOS management.

Conclusion

The comprehensive review of bioactive phytochemicals extracted from traditional Chinese medicine (TCM) and medicinal plants provides valuable insights into their potential as therapeutics for Polycystic Ovary Syndrome (PCOS). The exploration of flavonoids, polyphenols, and alkaloids has revealed diverse mechanisms of action, influencing various facets of PCOS, including oxidative stress, insulin resistance, hyperandrogenism, and ovarian morphology. Clinical studies have demonstrated promising effects on hormonal balance and reproductive outcomes, shedding light on the multifaceted nature of PCOS and the potential benefits of phytoconstituent interventions.

The findings presented in this review bear significant implications for the management of PCOS. Phytoconstituents, owing to their diverse pharmacological activities, offer a novel approach to address the complex and interconnected symptoms of PCOS. From mitigating insulin resistance to regulating

hormonal imbalances, these natural compounds present an alternative or complementary avenue for PCOS management. The potential of phytoconstituents to alleviate symptoms and improve reproductive outcomes introduces new possibilities for individualized and holistic treatment strategies in PCOS management.

While the current body of research provides promising insights, the field of phytoconstituents in PCOS management requires further exploration. Future research endeavors should focus on standardizing study designs, outcome measures, and patient populations to facilitate robust comparisons across studies. Long-term safety assessments and large-scale clinical trials are imperative to establish the efficacy and safety profile of phytoconstituent interventions. Mechanistic studies elucidating the precise pathways through which these compounds exert their effects will enhance our understanding and guide targeted interventions. Additionally, investigating potential synergies between phytoconstituents and conventional treatments can pave the way for integrated and personalized therapeutic approaches. Collaborative efforts between researchers, clinicians, and herbal medicine practitioners are crucial for advancing the field and translating research findings into effective and evidence-based interventions for PCOS management.

References:

1. Shrivastava S, Conigliaro RL. Polycystic ovarian syndrome. *Medical Clinics*. 2023 Mar 1;107(2):227-34. <https://doi.org/10.1016/j.mcna.2022.10.004>
2. Gao Y, Liu H, Qiao L, Liang J, Yao H, Lin X, Gao Y. Study of Burden in Polycystic Ovary Syndrome at Global, Regional, and National Levels from 1990 to 2019. *InHealthcare* 2023 Feb 14 (Vol. 11, No. 4, p. 562). MDPI. <https://doi.org/10.3390/healthcare11040562>
3. Artyomenko V, Velychko V, Lahoda D, Danylchuk H. Common clinical laboratory features among women with polycystic ovary syndrome and metabolic syndrome. *Journal of Medicine and Life*. 2023 Aug;16(8):1215. doi: 10.25122/jml-2023-0057
4. Chavez GN, Jaworsky K, Basu A. The Effects of Plant-Derived Phytochemical Compounds and Phytochemical-Rich Diets on Females with Polycystic Ovarian Syndrome: A Scoping Review of Clinical Trials. *International Journal of*



- Environmental Research and Public Health. 2023 Aug 6;20(15):6534. <https://doi.org/10.3390/ijerph20156534>
5. Luo ED, Jiang HM, Chen W, Wang Y, Tang M, Guo WM, Diao HY, Cai NY, Yang X, Bian Y, Xing SS. Advancements in lead therapeutic phytochemicals polycystic ovary syndrome: A review. *Frontiers in Pharmacology*. 2023 Jan 9;13:1065243 <https://doi.org/10.3389/fphar.2022.1065243>
6. Koike H, Harada M, Kusamoto A, Xu Z, Tanaka T, Sakaguchi N, Kunitomi C, Azhary JM, Takahashi N, Urata Y, Osuga Y. Roles of endoplasmic reticulum stress in the pathophysiology of polycystic ovary syndrome. *Frontiers in endocrinology*. 2023 Feb 15;14:1124405. <https://doi.org/10.3389/fendo.2023.1124405>
7. Sikiru AB, Adeniran MA, Akinola K, Behera H, Kalaignazhal G, Egena SS. Unraveling the complexity of the molecular pathways associated with polycystic ovary syndrome (PCOS) and identifying molecular targets for therapeutic development: a review of literature. *Middle East Fertility Society Journal*. 2023 Jun 30;28(1):16. <https://doi.org/10.1186/s43043-023-00142-w>
8. Mukherjee K, Biswas R, Chaudhary SK, Mukherjee PK. Botanicals as Medicinal Food and Their Effects against Obesity. In: Mukherjee PK, editor. *Evidence-Based Validation of Herbal Medicine*. Elsevier; 2015. p. 373-403. <https://doi.org/10.1016/B978-0-12-800874-4.00018-0>
9. Siddique R, Mehmood MH. Role of complementary and alternative medicine in polycystic ovary syndrome. In: Rehman R, Sheikh A, editors. *Polycystic Ovary Syndrome*. Elsevier; 2024. p. 171-180. <https://doi.org/10.1016/B978-0-323-87932-3.00031-1>
10. Garg M, Chaudhary SK, Goyal A, Sarup P, Kumari S, Garg N, Vaid L, Shiveena B. Comprehensive review on therapeutic and phytochemical exploration of diosmetin: A promising moiety. *Phytomedicine Plus*. 2022;2(1):100179. <https://doi.org/10.1016/j.phyplu.2021.100179>
11. Gautam K, Raina R, Dikshit N. Current Knowledge on Sustainability and Conservation of Endangered Himalayan Medicinal Herb *Angelica glauca* Edgew.—a Review. *Journal of Herbal Medicine*. 2023;42:100764. <https://doi.org/10.1016/j.hermed.2023.100764>
12. Dashputre NL, Laddha UD, Patil SB, Kadam JD, Kshirsagar SJ. An insight to development and in-vitro, ex-vivo, in-vivo study of naringenin nanoparticles against letrozole induced polycystic ovarian syndrome in female wistar rats. *Journal of Drug Delivery Science and Technology*. 2023;90:105129. <https://doi.org/10.1016/j.jddst.2023.105129>
13. Mishra Y, Amin H, Mishra V, Vyas M, Prabhakar PK, Gupta M, Kanday R, Sudhakar K, Saini S, Hromić-Jahjefendić A, Aljabali AAA, El-Tanani M, Serrano-Aroca Ñ, Bakshi H, Tambuwala MM. Application of nanotechnology to herbal antioxidants as improved phytomedicine: An expanding horizon. *Biomedicine & Pharmacotherapy*. 2022;153:113413. <https://doi.org/10.1016/j.biopha.2022.113413>
14. Kulkarni S, Gupta K, Ratre P, Mishra PK, Singh Y, Biharee A, Thareja S. Polycystic ovary syndrome: Current scenario and future insights. *Drug Discovery Today*. 2023;28(12):103821. <https://doi.org/10.1016/j.drudis.2023.103821>
15. Bailly C. Efficacy and safety of the traditional herbal medication Chai-Ling-Tang (in China), Siryung-tang (in Republic of Korea) or Sairei-To (in Japan). *Journal of Ethnopharmacology*. 2024;319(Part 1):117127. <https://doi.org/10.1016/j.jep.2023.117127>
16. Maphetu N, Unuofin JO, Masuku NP, Olisah C, Lebelo SL. Medicinal uses, pharmacological activities, phytochemistry, and the molecular mechanisms of *Punica granatum* L. (pomegranate) plant extracts: A review. *Biomedicine & Pharmacotherapy*. 2022;153:113256. <https://doi.org/10.1016/j.biopha.2022.113256>
17. Singh N, Yadav SS, Kumar S, Narashiman B. Ethnopharmacological, phytochemical and clinical studies on Fenugreek (*Trigonella foenum-graecum* L.). *Food Bioscience*. 2022;46:101546. <https://doi.org/10.1016/j.fbio.2022.101546>
18. Obika P, Beamon J, Ali S, et al. Herbal medicines for the treatment of metabolic syndrome. *Herbal Medicines*. 2022. <https://doi.org/10.1016/B978-0-323-90572-5.00007-X>
19. Siddhartha Pati, Tanmay Sarkar, Dibyajit Lahiri (Editors). *Polycystic Ovary Syndrome*. Elsevier,



2024. ISBN 9780323879323.
<https://doi.org/10.1016/B978-0-323-87932-3.00040-2>
20. Deependra Singh, Krishna Yadav, Manju Rawat Singh, Narayan D. Chaurasiya, Babu L. Tekwani. "Novel drug delivery approaches for improving therapeutic applications of berberine and berberine-rich herbal preparations." Academic Press, 2023. ISBN 9780323991254.
<https://doi.org/10.1016/B978-0-323-99125-4.00016-0>
21. Ricardo Lagoa, João Silva, Joaquim Rui Rodrigues, Anupam Bishayee. "Advances in phytochemical delivery systems for improved anticancer activity." Biotechnology Advances, 2020, Volume 38, 107382. ISSN 0734-9750.
<https://doi.org/10.1016/j.biotechadv.2019.04.004>
22. Ronald Ross Watson, Victor R. Preedy (Editors). "Bioactive Food as Dietary Interventions for Diabetes." Academic Press, 2013. ISBN 9780123971531. <https://doi.org/10.1016/B978-0-12-397153-1.09991-1>
23. Monika Joshi, Ravi Shankar, Kamla Pathak, Ramakant Yadav. "Polycystic ovarian syndrome: A review covering phytoconstituents for its outstrip management." Pharmacological Research - Modern Chinese Medicine, 2021, Volume 1, 100011. ISSN 2667-1425.
<https://doi.org/10.1016/j.prmcm.2021.100011>
24. Alexander V. Sirotkin, Adriana Kolesarova (Editors). "Food/medicinal herbs and their influence on health and female reproduction." Academic Press, 2022. ISBN 9780128242926.
<https://doi.org/10.1016/j.prmcm.2021.100011>
25. Manash Pratim Pathak, Kalyani Pathak, Riya Saikia, Urvashee Gogoi, Pompy Patowary, Pronobesh Chattopadhyay, Aparoop Das. "Therapeutic potential of bioactive phytoconstituents found in fruits in the treatment of non-alcoholic fatty liver disease: A comprehensive review." Heliyon, 2023, Volume 9, Issue 4, e15347. ISSN 2405-8440.
<https://doi.org/10.1016/j.heliyon.2023.e15347>
26. Raksha Rani, Younis Ahmad Hajam, Rajesh Kumar, Rouf Ahmad Bhat, Seema Rai, Manzoor Ahmad Rather. "A landscape analysis of the potential role of polyphenols for the treatment of Polycystic Ovarian Syndrome (PCOS)." Phytomedicine Plus, 2022, Volume 2, Issue 1, 100161. ISSN 2667-0313.
<https://doi.org/10.1016/j.phyplu.2021.100161>
27. Alexa Florina Bungau, Andrei Flavius Radu, Simona Gabriela Bungau, Cosmin Mihai Vesa, Delia Mirela Tit, Laura Maria Endres. "Oxidative stress and metabolic syndrome in acne vulgaris: Pathogenetic connections and potential role of dietary supplements and phytochemicals." Biomedicine & Pharmacotherapy, 2023, Volume 164, 115003.
<https://doi.org/10.1016/j.biopha.2023.115003>
28. Lakshmi JN, Babu AN, Kiran SM, Nori LP, Hassan N, Ashames A, Bhandare RR, Shaik AB. Herbs as a source for the treatment of polycystic ovarian syndrome: A systematic review. BioTech. 2023 Jan 3;12(1):4.
<https://doi.org/10.3390/biotech12010004>
29. Balieiro CC, Hespanhol LC, Fonseca LM, Wantowski S, Freitas MA, Dias YJ, Burlá MM, de Oliveira LM. Effects of polyphenol in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2023 Dec 30.
<https://doi.org/10.1016/j.ejogrb.2023.12.038>
30. Almeida Balieiro CC, Hespanhol LC, Araújo Freitas MA, de Oliveira LM. THU637 The Effects Of Polyphenol On Insulin Resistance And Hormonal Parameters On Women With Polycystic Ovary Syndrome: A Systematic Review And Meta-analysis Of Randomized Controlled Trials. Journal of the Endocrine Society. 2023 Oct;7(Supplement_1):bvad114-1541 <https://doi.org/10.1210/jendso/bvad114.1541>
31. Moka MK. Computational investigation of four isoquinoline alkaloids against polycystic ovarian syndrome. Journal of Biomolecular Structure and Dynamics. 2023 Jun 7:1-3.
<https://doi.org/10.1080/07391102.2023.2222828>